Loading logo

Ruxolitinib Impurities

Ruxolitinib is a selective Janus kinase (JAK) inhibitor commonly used under the brand name Jakafi for the treatment of myelofibrosis and polycythemia vera. By targeting JAK1 and JAK2 enzymes, it helps regulate the overactive signaling pathways involved in these hematologic disorders. Maintaining the pharmaceutical purity of Ruxolitinib is essential to ensure its therapeutic efficacy, patient safety, and adherence to regulatory standards. Impurity profiling is crucial for detecting and controlling unwanted by-products that may arise during manufacturing, storage, or degradation. Here are some of its known impurities listed below.

Showing 1 - 5 of 5 products
Ruxolitinib Amide
Catalogue No : RUXO-OCL-005

CAS No : 1911644-32-0

In Stock
Synonyms
3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanamide
Ruxolitinib Racemate
Catalogue No : RUXO-OCL-001

CAS No : 941688-05-7

In Stock
Synonyms
β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile
Ruxolitinib RC 1
Catalogue No : RUXO-OCL-002

CAS No : 941685-26-3

In Stock
Synonyms
4-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine
Ruxolitinib RC 2
Catalogue No : RUXO-OCL-003

CAS No : 941685-27-4

In Stock
Synonyms
4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine
Ruxolitinib RC 3
Catalogue No : RUXO-OCL-004

CAS No : 952518-97-7

In Stock
Synonyms
4-(1H-Pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine